Inherent Biosciences and Seattle Sperm Bank present a novel and exciting approach to qualifying sperm donors

Salt Lake City, Utah — Inherent Biosciences, a biotechnology company pioneering epigenetic medicine, and Seattle Sperm Bank, the nation’s most trusted sperm donor resource, today shared their Poster Presentation at the American Society of Andrology Annual Meeting in Boston.

Here are the key takeaways:

• There is an extreme shortage of sperm donors globally

• The current post thaw motile concentration (PTMC) cutoff - a number created arbitrarily - restricts the number of sperm donors that can be used for IUI and is not predictive of live birth outcomes 

• Additional metrics are needed to qualify sperm donors for IUI procedures

• Using SpermQT to examine epigenetic profiles of these sperm samples could help qualify more sperm donors

• The IUI-grade and non-IUI grade sperm samples from the same donors have similar epigenetic signatures

• Non-IUI-grade samples with Normal or Excellent SpermQT results could be used in IUI procedures

For all of the details, click here to view our poster.

About Inherent Biosciences

Inherent Biosciences, Inc. is a biotechnology company pioneering epigenetic medicine for complex diseases. Gene dysregulation, a hallmark of complex disease, has been difficult to detect and treat, until now. The company’s epigenetic platform detects dysregulation across multiple genes and related pathways to pioneer a new category of diagnostics and therapeutics that leverage epigenetics, biology’s inherent mechanism for gene regulation, to radically transform how we diagnose and treat complex diseases like infertility.

Connect with us on LinkedIn.